Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038

QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S.

Read more at globenewswire.com